Elanco Animal Health (NYSE:ELAN) Price Target Raised to $24.00

Elanco Animal Health (NYSE:ELAN) had its target price hoisted by Morgan Stanley from $22.00 to $24.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

A number of other research firms also recently issued reports on ELAN. Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Wednesday, November 19th. Zacks Research lowered shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. JPMorgan Chase & Co. increased their price objective on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, February 19th. Finally, KeyCorp boosted their target price on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Elanco Animal Health Trading Up 0.6%

NYSE:ELAN opened at $26.35 on Wednesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.23. The firm has a 50-day moving average of $24.23 and a 200-day moving average of $21.76. The company has a market cap of $13.10 billion, a PE ratio of -54.90, a PEG ratio of 3.38 and a beta of 1.87. Elanco Animal Health has a one year low of $8.02 and a one year high of $27.72.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, equities research analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Activity at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons purchased 22,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the purchase, the chief executive officer directly owned 167,000 shares in the company, valued at approximately $3,632,250. This trade represents a 15.17% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert M. Vanhimbergen purchased 6,950 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average cost of $21.64 per share, for a total transaction of $150,398.00. Following the acquisition, the chief financial officer directly owned 124,233 shares in the company, valued at $2,688,402.12. This trade represents a 5.93% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 43,450 shares of company stock valued at $937,883 over the last quarter. 0.89% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Elanco Animal Health

Several large investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC lifted its holdings in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares during the last quarter. SJS Investment Consulting Inc. raised its position in shares of Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares during the period. Root Financial Partners LLC lifted its stake in shares of Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new position in Elanco Animal Health in the 4th quarter worth approximately $41,000. Finally, Huntington National Bank grew its stake in Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.